Diagnostic markers based on a computational model of lipoprotein metabolism by van Schalkwijk, Daniël B et al.
METHODOLOGY Open Access
Diagnostic markers based on a computational
model of lipoprotein metabolism
Daniël B van Schalkwijk
1,2,3*, Ben van Ommen
1, Andreas P Freidig
4, Jan van der Greef
1,2 and Albert A de Graaf
1
Abstract
Background: Dyslipidemia is an important risk factor for cardiovascular disease and type II diabetes. Lipoprotein
diagnostics, such as LDL cholesterol and HDL cholesterol, help to diagnose these diseases. Lipoprotein profile
measurements could improve lipoprotein diagnostics, but interpretational complexity has limited their clinical
application to date. We have previously developed a computational model called Particle Profiler to interpret
lipoprotein profiles. In the current study we further developed and calibrated Particle Profiler using subjects with
specific genetic conditions. We subsequently performed technical validation and worked at an initial indication of
clinical usefulness starting from available data on lipoprotein concentrations and metabolic fluxes. Since the model
outcomes cannot be measured directly, the only available technical validation was corroboration. For an initial
indication of clinical usefulness, pooled lipoprotein metabolic flux data was available from subjects with various
types of dyslipidemia. Therefore we investigated how well lipoprotein metabolic ratios derived from Particle Profiler
distinguished reported dyslipidemic from normolipidemic subjects.
Results: We found that the model could fit a range of normolipidemic and dyslipidemic subjects from fifteen out
of sixteen studies equally well, with an average 8.8% ± 5.0% fit error; only one study showed a larger fit error. As
initial indication of clinical usefulness, we showed that one diagnostic marker based on VLDL metabolic ratios
better distinguished dyslipidemic from normolipidemic subjects than triglycerides, HDL cholesterol, or LDL
cholesterol. The VLDL metabolic ratios outperformed each of the classical diagnostics separately; they also added
power of distinction when included in a multivariate logistic regression model on top of the classical diagnostics.
Conclusions: In this study we further developed, calibrated, and corroborated the Particle Profiler computational
model using pooled lipoprotein metabolic flux data. From pooled lipoprotein metabolic flux data on dyslipidemic
patients, we derived VLDL metabolic ratios that better distinguished normolipidemic from dyslipidemic subjects
than standard diagnostics, including HDL cholesterol, triglycerides and LDL cholesterol. Since dyslipidemias are
closely linked to cardiovascular disease and diabetes type II development, lipoprotein metabolic ratios are
candidate risk markers for these diseases. These ratios can in principle be obtained by applying Particle Profiler to a
single lipoprotein profile measurement, which makes clinical application feasible.
Background
Dyslipidemia is an important risk factor for cardiovascu-
lar disease and type II diabetes. Especially low-density
lipoprotein (LDL) cholesterol and LDL particle concen-
trations are known to be positively associated with car-
diovascular disease risk [1], and reaching low LDL
cholesterol concentrations is a primary goal for therapy
[2]. Other recognized markers for metabolic syndrome
include triglycerides and HDL cholesterol [2]. LDL par-
ticles contain the protein apoB, and are to a large extent
a metabolic product of the larger apoB-containing lipo-
proteins, very low density lipoproteins (VLDL), and
intermediate-density lipoproteins (IDL). Technological
advances allow the full size spectrum of lipoproteins to
be measured in increasing detail [3-7], creating a
detailed lipoprotein profile. Although such a profile con-
tains much information, it has not led to a single diag-
nostic value that is easily applicable. The detailed
lipoprotein profile needs a further interpretation and
validation to be useful for the clinic. One example of
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particles, and reporting an ‘LDL particle number’.T h i s
diagnostic has proven to be successful at predicting car-
diovascular risk [1]. Still, the detailed lipoprotein profiles
contain more information that is discarded when only
reporting LDL particles. A computational model that
can characterize the state of metabolic processes affect-
ing lipoproteins, based on the additional information
contained in a lipoprotein profile, may be of added
value in the clinic.
Lipoprotein metabolism of VLDL, IDL, and LDL com-
prises three main processes. The lipoproteins are pro-
duced by the liver, then lose triglycerides through lipolysis
and are finally taken up from the bloodstream by the liver.
The lipolysis process occurs in extrahepatic tissues
through lipoprotein lipase (LPL), which mainly affects the
larger very-low-density lipoproteins (VLDL) [8], whereas
in the liver lipolysis occurs through hepatic lipase (HL),
mainly affecting the smaller IDL and LDL [9,10]. LPL
activity is also known to affect HDL metabolism [11].
Measuring the rates of these processes is generally carried
out using stable-isotope or radioactive-isotope tracer tech-
niques. The most popular approaches perform kinetic tra-
cer analysis of the large constituent protein apolipoprotein
B to obtain lipoprotein fluxes [12]. These techniques are
costly and labor-intensive. A good characterization of the
status of lipoprotein metabolism is, therefore, an extensive
and difficult procedure at this time.
Since it would be helpful to get an impression of lipo-
protein metabolism in a fast and less laborious way, we
have developed a computational model called Particle
Profiler [13,14]. This model was designed to derive
ratios between the various lipoprotein metabolic pro-
cesses, such as the ratio between lipolysis and produc-
tion, from a single lipoprotein profile. Figure 1 shows
how in the model development phase, reported in the
Figure 1 Data use and generation in current and future model implementations. In the current study, we used Particle Profiler as indicated
below the vertical bar. Pooled lipoprotein flux data was used for fitting the model to data of individual subjects, and the fitted model was used
to generate lipoprotein particle flux data and lipoprotein metabolic ratios. The light blue area illustrates the final application we aim at. In that
application, Particle Profiler will be applied to lipoprotein profile data, which allows for the quantification of lipoprotein metabolic ratios only.
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tein fluxes and lipoprotein metabolic ratios from pre-
viously published pooled lipoprotein flux data (see e.g.
[15]). This ‘pooled lipoprotein flux data’ includes particle
concentrations and fluxes (production, lipolysis and
uptake) in four size classes: VLDL1, VLDL2, IDL and
LDL. Figure 1 also shows that the future application to
lipoprotein profiles will not be able to produce particle-
based lipoprotein fluxes, but only lipoprotein metabolic
ratios. It is impossible to obtain the absolute fluxes,
since the lipoprotein profile measurements are taken
from a single blood sample and do not contain kinetic
information. Still, the metabolic ratios show whether
metabolic processes are well balanced or not, which
could give an indication of health status.
Clinical application of the previously published Parti-
cle Profiler model [13] requires further model develop-
ment and calibration, as well as both technical and
clinical validation. Model development and calibration
are necessary to overcome previously identified short-
comings (see model development below). Technical vali-
dation needs to ensure that the model is able to
accurately reflect lipoprotein metabolism, as measured
by experiment in a wide range of subjects. In the model,
the metabolic rate of a particle depends on its size.
Using the metabolic rate information of each particle,
the model can calculate the average metabolic rate of
particles in a certain size range of interest, for instance
the VLDL size range (see [13]). The model also distin-
guishes different metabolic routes, such as particle lipo-
lysis through LPL or HL. It is impossible to measure
these quantities directly. Instead, a feasible approach to
technical validation is to calibrate the model with pooled
lipoprotein flux data from genetically deficient subjects,
and subsequently corroborate it with pooled lipoprotein
flux data from a range of different normolipidemic and
dyslipidemic subjects. Calibration and subsequent corro-
boration with pooled lipoprotein flux data is the only
available route of technical validation. Subsequent steps
of clinical validation should point out whether the
values produced by Particle Profiler correctly inform
about disease status.
In this study we address two questions. First, whether
a further developed and calibrated Particle Profiler
model could be corroborated with pooled lipoprotein
flux data from a range of different normolipidemic and
dyslipidemic subjects. Second, whether Particle Profiler-
based ratios of VLDL metabolic processes derived from
pooled lipoprotein flux data indicate relevant differences
between dyslipidemic and normolipidemic subjects.
Continuing on from the second question, we also exam-
ined the effect of statin and fibrate treatment on the
VLDL metabolic ratios.
Results
Algorithm development
The initial Particle Profiler model [13]
1 includes func-
tions that specify the following processes: production,
liver attachment, lipolysis through a hepatic HL-related
process and an extrahepatic LPL-related process, and
uptake through an apoB and an apoE-related process.
Liver attachment is immediately followed either by HL-
related lipolysis or one of the uptake processes. The
model includes VLDL, IDL and LDL particles.
The mathematical functions describing liver uptake
and lipolysis needed further development for two rea-
sons. First of all, for three out of sixteen analyzed sub-
jects in our first paper, the model was not able to
reproduce the lipoprotein fluxes well. The deviation was
mainly due to the uptake fluxes, suggesting that the
mathematical functions used to model uptake processes
were suboptimal. Secondly, a parameter identifiability
analysis, using the covariance matrix produced by the
parameter fitting routine (data not shown), showed that
detailed lipoprotein profiles, in contrast to lipoprotein
kinetics data, do not contain enough information to fit
the six parameters in the original model. Because of
problem for future model applications to lipoprotein
profile data, we decided to reduce the dimensionality of
the model by one parameter to five parameters through
simplifying the hepatic lipolysis function. We expect
that this necessary simplification wil reduce model per-
formance, but by smart reduction and subsequent cali-
bration we attempt to limit the performance reduction.
Since the both the uptake and hepatic lipase functions
relate to liver processes, we introduced new functions
for lipoprotein attachment to the liver, and lipoprotein
lipolysis and uptake by the liver.
The new model of liver-related aspects of lipoprotein
metabolism describes the biological process as two phases,
similar to the earlier model. In the first phase, the particle
is attached to the liver via either apoB- or apoE-related
mechanisms. In the second phase, particles attached
through the apoB-related mechanism are directly taken up,
whereas particles attached through the apoE-related
mechanism can be either taken up or lipolyzed. The prob-
ability that a particle is taken up or lipolyzed depends on
the size of the particle, with larger particles having a greater
probability of being taken up instead of lipolyzed [13].
The full development of the new functions is
described in Additional file 1; all symbols used in the
equations in this paper are defined in Table 1. The new
function describing how the liver attachment rate ka, liver
varies with particle size d is based on the Weibull distri-
bution; the Rayleigh distribution was used in the pre-
vious implementation [13]. The main advantage of the
Weibull function is its ability to take on different shapes,
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liver uptake. The new function is given by (eq. 1):
for d <da, apoE min
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for d <da, apoE min
ku,liver(d)=ka,apoB
Where ka, liver max is the maximum liver attachment
rate, ka, apoB is the apoB-related liver attachment rate,
da, apoE min is the minimum particle size at which apoE-
related liver attachment takes place, and A and B are
shape parameters.
The model specifies that once a particle has been
attached it is either directly taken up or lipolyzed. In
Table 1 Overview of state variables, variables, parameters and constants used in this paper
State Variables - determine the system state
di, j nm Lipoprotein particle diameter in the i-th step of a lipolysis cascade, in the j-th subclass of the size range
covered by that cascade step
Qss (di, j) Particles * dL
-1 Steady-state particle pool size in a pool with mean particle diameter di, j
Variables - specify processes and output
dr
i,j nm the radius of the subclass with average diameter di, j
Jl (di, j) Particles *
dL
-1 * day
-1
Particle flux into the pool with mean particle diameter di, j due to extrahepatic lipolysis
Jl, liver (di, j) Particles *
dL
-1 * day
-1
Particle flux into the pool with mean particle diameter di, j due to hepatic lipolysis
kl(d) day
-1 Particle size dependent extrahepatic lipolysis rate
ka, liver day
-1 Particle size dependent liver attachment rate
(attachment is followed by either lipolysis or uptake)
kl, liver (d) day
-1 Particle size dependent liver lipolysis rate
ku, liver (d) day
-1 Particle size dependent liver uptake rate
ntg (di, j) Molecules * particle
-1 Number of triglyceride molecules in a lipoprotein particle with diameter di, j
Q* Particles * dL
-1 Steady-state particle pool size in the size range called *
k∗
u,liver day
-1 Particle size dependent liver uptake rate, averaged per particle over the size range called *
kl day
-1 Particle size dependent extrahepatic lipolysis rate, averaged per particle over all particles in the model
ka,liver day
-1 Particle size dependent liver attachment rate, averaged per particle over all particles in the model
Jp,* Particles * dL
-1*day
-1 Particle production flux into the size range called *
Jin, * Particles *
dL
-1 * day
-1
Particle production influx (production + lipolysis) into the size range called *
Qout ([da db]) Particles * dL
-1 Steady state particle pool size in interval from da todbin the final particle concentration profile.
Parameters - are optimized using data
kl, max day
-1 maximum rate at which extrahepatic lipolysis takes place
ka, apoEmax day
-1 maximum rate at which liver binding mediated by ApoE takes place
ka, apoB day
-1 rate at which liver binding mediated by ApoB takes place
A nm shape parameter for liver binding mediated by ApoE
B - shape parameter for liver binding mediated by ApoE
su, liver nm shape parameter describing fraction of liver attachment which is taken up (instead of lipolyzed) - with
changing particle size
Model constants and derived variables - calibrated in this paper
da, apoEmin 17 nm minimum particle diameter at which liver binding mediated by ApoE takes place
dhl, peak 31.33 nm Hepatic lipase lipolysis peak size (see Eq. 5)
su, liver 7.87 Liver uptake shape constant (see Eq. 2)
dl, min 25.13 nm minimum size at which extrahepatic lipolysis occurs (see Eq. 4 in [13])
sl 77.35 nm shape constant for extrahepatic lipolysis (see Eq. 4 in [13])
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smaller particles are taken up more often, although the
exact rates differ per individual. The function describing
how the lipolysis/uptake ratio varies with particle size
also was a Rayleigh distribution in the previous model
implementation. In the new model implementation this
function is described using a Weibull distribution. The
new equation for liver uptake, modeled as liver attach-
ment followed by uptake, is given by (eq. 2):
For d <da, apoE min
ku,liver(d)=
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For d <da, apoE min
ku,liver(d)=ka,apoB
Where all symbols have the same meaning as before,
and su, liver is a liver uptake constant, that helps to
determine the shape of the uptake function. The Wei-
bull function normally has two shape parameters, but
the available data do not contain enough information to
fit both. Therefore we gave su, liver a constant value that
does not vary between patients, but that we optimize
under ‘model calibration’. su, liver is a liver uptake shape
parameter that does vary between patients and can be
adjusted in parameter optimization.
Since in the model, the attached particles that are not
taken up are lipolyzed, the equation for liver lipolysis kl,
liver is:
kl,liver(d)=ka,liver(d) − ku,liver(d) (3)
The figures in Additional file 1 show the new version
of the liver attachment, lipolysis and uptake functions.
In the methods section we define the dhl, peak constant
that describes the particle size at which hepatic lipase
activity is at its peak. By fixing this constant, we reduced
the free parameters in the model from six to five. Table
1 gives an overview of what parameters were optimized
(fitted) using the patient’s data in the current
implementation.
Model Calibration
The model equations contain parameters that are
allowed to assume different values for different patients
and model constants that are fixed to the same value for
all patients. The model constants contain the biological
information that, for instance, allows the model to dis-
tinguish hepatic lipolysis from extrahepatic lipolysis.
Therefore, it is very important that these constants have
the correct values. The constants optimized here are:
dhl, peak, su, liver, sa, lpl and da, lpl min, which are related
to HL lipolysis, liver uptake and LPL lipolysis (2 con-
stants) respectively (see Table 1 for an overview of all
notation). The first two constants are new to the model,
the last two were already present in the first version
[13], but are now given new values. To estimate the
model constants, one needs data from subjects in which
particular process stands out clearly. Below, we first
describe what data we used to estimate specific con-
stants, and in continuation we describe how the con-
stants were estimated.
To estimate the HL-related model constant dhl, peak,
which indicates the lipoprotein particle size at which HL
activity is highest, we used patients with lipoprotein
lipase (LPL) deficiency. In these patients the only
remaining lipolysis activity is due to HL. Data on lipo-
protein metabolic fluxes in such patients came from
[16].
To estimate the model constant su, liver, which helps to
model the liver uptake rate at different lipoprotein parti-
cle sizes, subjects are needed in which uptake processes
take place with least interference from lipolysis pro-
cesses. By inspecting the kinetic data, we found that
normolipidemic ApoE 3/3 subjects meet these criteria
best. Therefore, su, liver was estimated using data on lipo-
protein metabolic fluxes in ApoE 3/3 subjects from [17].
To estimate model constants related to LPL lipolysis,
subjects with the ApoE 2/2 genotype were used. Sub-
jects with the ApoE 2/2 isoform are known to have
impaired uptake of large VLDL and chylomicron parti-
cles [17]. Since VLDL particles can either be taken up
by the liver or lipolyzed by LPL, an impaired uptake
means that the LPL lipolysis process, that mainly takes
place in the VLDL size range, can be distinguished
clearly. Also, the lipolysis of smaller particles was found
to be impaired in ApoE 2/2 subjects [17], indicating a
less effective hepatic lipase function, which should make
the LPL activity even more clearly discernable, also for
smaller particles. Therefore, the data from subjects with
the ApoE 2/2 phenotype were useful for estimating two
model constants related to LPL: sa, lpl and da, lpl min.
Because in apoE 2/2 patients hepatic lipase function is
inhibited, the model needed to be adjusted slightly. We
allowed the ‘HL peak size’ (dhl, peak) parameter to be
optimized for each individual apoE 2/2 subject, which is
otherwise constant for all subjects. In this way the
model could better handle the special condition of very
low HL activity.
In order to determine the model constants via para-
meter fitting, a double-layered fitting routine was con-
structed. On the first layer, the algorithm searched for
the optimal value for the model constant. The second
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each selected constant value. Both layers used the
Levenberg-Marquardt algorithm as implemented in
MATLAB’s nlinfit method of version 7.7.0 (R2008b) for
fitting the constants and parameters respectively. The
used error functions can be found in the methods sec-
tion. Parameter identifiability was inspected using the
covariance matrix produced by the fitting routine. In
this way, the model parameters were estimated per indi-
vidual, while the model constants were estimated for the
whole population, using a group of patients judged most
suited for the determination of that constant.
We chose to fit the constants in the same order as
they were discussed above: first hepatic lipase constants,
then liver uptake constants, and finally LPL lipolysis
constants. Each time the newly found constant value
was used in the process of fitting the subsequent con-
stants. The order of fitting and the type of subjects, dis-
cussed above, were chosen in such a way that the
constants that had not yet been fitted exerted minimal
influence on the constant being fitted. For instance, the
LPL deficient patients used for determining the Hepatic
Lipase constants have little LPL activity and little liver
uptake activity related to the unknown uptake constants.
The model constants obtained from the optimization
process are given in Table 1. The constants show that
Hepatic Lipase activity is highest in particles around 31
nm in size, which is the IDL and small VLDL2 size
range. Instead, LPL lipolysis affects particles of approxi-
mately 25 nm (lower cutoff) and higher, but the large
shape parameter sl indicates that the LPL rate very gra-
dually increases with size, and really becomes important
for the larger VLDL2 and the VLDL1 particles, which
LPL is known to affect more. The translation into exact
metabolic rates depends on the model parameters that
differ for every subject (shown in Table 1).
Comparison with earlier results
With the new model equation and settings, we exam-
ined whether the results are comparible to those in our
first paper [13]. The subjects reported by Packard et al.
[18] were fitted with the new model and the results
were compared with those from the first model imple-
mentation [13]. In the first implementation, the model
reproduced a shift in ‘LDL peak size’, which was inde-
pendently measured. The model analysis also identified
credible changes in relevant biological processes
between groups with differing ‘LDL peak size’. For the
new model, we examined how well the data was fitted,
whether the shift in ‘LDL peak size’ was still reproduced
by the model, and whether the model still identified
similar differences in biological processes between
groups with differing ‘LDL peak size’.S i n c et h em o d e l s
are different and the new model has one free parameter
less, which in general leads to less optimal model per-
formance, we did not expect an exact match between
the model results. This comparison does show what
similarities and differences exist.
The model with optimized constants and one free
parameter less than in the first implementation [13]
reproduced the data from Packard et al.[ 1 8 ]w e l l .T h e
overall fit error, defined in [13], was 7.3% ± 3.6% in this
study compared to a 7.2% ± 4.5% error in our first
paper. In [13] the model calculated a difference in LDL
size of 4.2 nm between subjects with phenotype ‘A’
(large LDL particles) versus phenotype ‘ B’ (small LDL
particles). This LDL size difference was significant, with
a Kruskal-Wallis p-value of 0.026. In the new implemen-
tation we saw a similar difference, although with 1.9 nm
it was less pronounced. The Kruskal-Wallis test indi-
cated a trend, with p = 0.089. The most likely cause of
this difference is the description of hepatic lipolysis,
which lost one free parameter in the new model. This
conjecture was confirmed by studying the difference in
metabolic processes between subjects with phenotypes
‘A’ and ‘B’ from [18], as analyzed by our initial model
versus the new implementation. The latter are shown in
Table 2. As observed earlier [13], we saw differences in
the average particle lipolysis rate in VLDL 1 and VLDL
2, and in the average particle uptake rate in LDL
between ‘A’ and ‘B’ phenotypes. In contrast to our first
study [13], no differences between the two phenotypes
were found for HL lipolysis in LDL. Instead differences
were found in uptake of IDL particles and LPL lipolysis
of VLDL and IDL. For particle age similar differences
between ‘A’ and ‘B’ phenotypes were found in LDL,
VLDL2 and VLDL1, as well as an additional difference
in IDL age. For particle size differences between pheno-
types were found for LDL and IDL, and for the new
implementation an additional difference in VLDL1 parti-
cle diameter was found. Overall this comparison indi-
cates that the new implementation made the model less
sensitive to changes in LDL metabolism, but increased
its power to identify changes in LPL lipolysis in the
VLDL and IDL range, while the overall model fitting
performance did not change. So all in all we have car-
ried out a necessary simplification of the model, while
keeping the overall model performance stable.
Testing
Model corroboration
Particle Profiler calculates metabolic process rates
averaged per particle, and distinguishes between HL
and LPL lipolysis. Because these quantities cannot be
measured directly, the best way of validating the model
is through corroboration. Patients with different meta-
bolic conditions need to be modeled equally well.
Therefore, we applied Particle Profiler to lipoprotein
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subjects with a wide range of dyslipidemias that the
model had not yet analyzed before. We inspected
whether the model was able to fit data from all these
studies well. If successful, this indicates that the biol-
ogy incorporated in the model in the form of mathe-
matical equations is adequate to describe the measured
experimental data, or in other words that the model is
consistent with reality.
The overall fit error for the data from the different
lipoprotein kinetics studies was 10.4% with a standard
deviation of 6.5%. The highest errors were found when
analyzing data from Demant et al. 1998 [21], where the
fit error was 20.1% ± 6.4%. Many subjects in this study,
including the controls, had a high VLDL2 pool that our
model was unable to reproduce in conjunction with the
reported flux values. We cons i d e rt h ed e v i a t i o ni nt h i s
single study of small relevance, because it occurs not
only in the diseased subjects, but also in the controls.
Normolipidemic controls do not give problems in any
other study. Without these subjects the average fit error
was 8.8% ± 5.0%.
Implementation
We aim at applying Particle Profiler to lipoprotein pro-
files and deriving lipoprotein metabolic ratios, as illu-
strated in Figure 2. As a first step towards this
implementation, we here introduce two lipoprotein
metabolic ratios, which we calculate in this study by
applying Particle Profiler to pooled lipoprotein flux data.
Lipoprotein metabolic ratios for VLDL metabolism
Since overproduction of large VLDL particles is an
important characteristic of the atherogenic lipoprotein
phenotype [27], we first examined VLDL metabolism.
The only current clinical marker reflecting VLDL is
total plasma triglycerides, but this marker also includes
triglycerides in chylomicrons, IDL, LDL and HDL. The
marker introduced here relates more specifically to
VLDL.
Based on Particle Profiler, we derived ratios between
hepatic VLDL uptake and production, and between
LPL-related VLDL lipolysis and production. Since the
model calculates the metabolic rates of VLDL at each
particle size, this complex information needs to be inte-
grated into a single value. Therefore, we calculated three
ratios of metabolic rates of a VLDL particle. These are
kVLDL
l
Jp,VLDL
,
kVLDL
l
Jp,VLDL
, and VLDL performance, whose mathe-
matical definition can be found below. A schematic
introduction can be found in Figure 2. When referring
to the ‘VLDL metabolism ratios’ we refer to these three
ratios.
Table 2 Comparison with results of first paper [13]
Significance of inter-group difference Significance of inter-group difference
units p-value
[13]
p-value current
Size-specific process indicator parameters
Average particle lipolysis rate LDL day
-1 0.026 N.S.
Average particle lipolysis rate VLDL2 day
-1 0.026 0.014
Average particle lipolysis rate VLDL1 day
-1 0.005 0.007
Average particle LPL lipolysis rate IDL day
-1 N.S. 0.005
Average particle LPL lipolysis rate VLDL2 day
-1 N.S. 0.006
Average particle LPL lipolysis rate VLDL1 day
-1 N.S. 0.006
Average particle uptake rate LDL day
-1 0.042 0.052
Average particle uptake rate IDL day
-1 N.S. 0.042
Average particle HL attachment rate LDL day
-1 0.026 N.S.
Average particle HL attachment rate VLDL2 day
-1 0.034 N.S.
Size and age parameters
Average particle age LDL hours 0.014 0.031
Average particle age IDL hours N.S. 0.033
Average particle age VLDL2 hours 0.026 0.025
Average particle age VLDL1 hours 0.026 0.022
Average particle diameter LDL nm 0.027 0.089
Average particle diameter IDL nm 0.039 0.026
Average particle diameter VLDL1 nm N.S. 0.045
Significance of difference between groups with lipoprotein phenotypes A (LDL peak size < 25 nm), I (25 nm < LDL peak size < 26 nm) and B (LDL peak size > 26
nm) from [18] for size-specific indicator parameters. The results from the further developed and calibrated model versus the original model from are shown [13].
Only those processes that show a significant difference (p < 0.1) using the nonparametric Kruskal-Wallis test are included.
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kVLDL
u,liver
Jp,VLDL
can be
calculated from modeled values as follows (eq. 4):
kVLDL
u,liver
Jp,VLDL
=
R +
di,j≤db−
1
2
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i,j
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i,j
ku,liver
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Qss
 
di,j
 
QVLDL
Jp,VLDL
Where ku, liver(di, j) is the hepatic uptake rate and Qss
(di, j) is the concentration of particles in the subclass
with average diameter di, j . The meaning of subindices
i and j relates to the position of the subclass in the
lipolysis cascade, which is explained in [13] under
‘lipolysis cascades’. QVLDL and Jp, VLDL are the total
concentration of VLDL particles and total VLDL pro-
duction influx respectively, where VLDL covers the
size range from da =3 0n mto db =8 0n m . R is the
linearly interpolated small remainder for the boundary
subclasses, which partially fall in the selected range
(eq.4a):
Rlow =
 
di,j +
1
2
dr
i,j
 
− da
dr
i,j
· ku,liver
 
di,j
 
·
Qss
 
di,j
 
Qout
  
da,db
  
where da ∈ [di,j −
1
2
dr
i,j,di,j +
1
2
dr
i,j]
Rhigh =
db −
 
di,j −
1
2
dr
i,j
 
dr
i,j
· ku,liver
 
di,j
 
·
Qss
 
di,j
 
Qout
  
da,db
  
where db ∈ [di,j −
1
2
dr
i,j,di,j +
1
2
dr
i,j]
R = Rhigh + Rlow
Where dr
i,j represents the radius of the subclass with
average diameter di, j .
The ratio between LPL-related lipolysis and produc-
tion in VLDL (
kVLDL
l
Jp,VLDL
) is defined analogously, by repla-
cing ku, liver (di, j) in equations 4 and 4a by kl(di, j).
Figure 2 Graphical representation of the VLDL performance diagnostic. When applying the Particle Profiler model to a lipoprotein profile,
the uptake/production and lipolysis/production ratios in VLDL can be quantified. The information from these ratios can be summarized in a
single statistic taking the mean of these two ratios, which can be visualized as a projection on the identity line. We propose the name VLDL
performance for this projection. It integrates information about production, lipolysis and uptake rates, but can be calculated without metabolic
flux information, based on one detailed lipoprotein profile measured in one fasting blood sample.
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Page 8 of 16To show in a single value how efficiently produced
VLDL particles are metabolized, we introduce the
‘VLDL performance’ diagnostic, which is the average of
the previous two ratios.
VLDLperformance =
kVLDL
u,liver
Jp,VLDL
+
kVLDL
l
Jp,VLDL
2
Both ratios and VLDL performance have the dimen-
sion volume * particles
-1. Figure 2 graphically shows
how VLDL performance and the two ratios are related,
and how different disturbances in VLDL metabolism
affect VLDL performance.
General dyslipidemia
In order to obtain an indication of the clinical relevance
of our new markers for VLDL metabolism, we applied
the Particle Profiler model to a range of published stu-
dies with pooled lipoprotein flux data obtained in dysli-
pidemic subjects. Studies that contain both pooled
lipoprotein flux data and ‘hard’ endpoints such as
cardiovascular events are not available; dyslipidemia is
the closest possible alternative. In nearly all the selected
studies a group of healthy subjects and a group of
patients showing a specific type of dyslipidemia were
investigated and compared. Our pool of dyslipidemic
subjects was defined as all the subjects that were consid-
ered to be ‘dislipidemic’ in each study. To be included in
our analysis the studies also had to report data of stan-
dard clinical chemistry for comparison with our new
markers. Subjects for which the measured particle influx
and efflux differed more than 10% in one class (LDL,
IDL, VLDL1 or VLDL2) were judged not to be at steady
state and excluded from the dataset. A summary of the
data used for the analysis can be found in Table 3.
Since all these studies contain lipoprotein flux data, the
number of subjects measured is limited. The dyslipi-
demic state of the selected patients is always very clearly
distinguishable from the normolipidemic state, so that
an effect can be observed with a small number of
patients.
We tested whether particle Profiler-derived VLDL per-
formance was different for normolipidemic versus
Table 3 Subject groups used
Subject group Number of subjects Ref. Included in ‘normo-lipidemic’
group
Included in ‘dys-lipidemic’
group
Normolipidemic controls 3
(in: N1, N3, N5)
[19] x
Normolipidemic controls 6 [20] x
Normolipidemic controls: apoE 3/3 subjects. 5 [17] x
Normolipidemic controls 9 [21] x
All subjects 12 [22] x
phenotype ‘A’ (large LDL particle size) 9 [18] x
mixed dyslipidemia prior to treatment
(Baseline)
5
(in: P2, P3, P5, P7, P8)
[24] x
mixed dyslipidemia prior to treatment
(Baseline)
11 [25] x
kidney patients 9 [21] x
hypothyroid subjects before and during T4
therapy
10
(excluded before T4: 6;
during T4: 3)
[26] x
HIV treatment-associated hyperlipidemic
subjects
5 [23] x
phenotype ‘B’ subjects, with small LDL particle
size
4
(in: subjects 17-20)
[18] x
LPL -/- 3 [16]
apoE 2/2 4 [17]
apoE 4/4 5 [17]
homozygous familial hypercholesterolemia 3
(in: FH1, FH2, FH4)
[19]
familial defective apoB 3 [29]
S447X; a single nucleotide polymorphism in
the LPL gene
5 [30]
Total used for normolipidemic group 44
Total used for dyslipidemic group 44
Subject groups used for normolipidemia, dyslipidemia, and genetic disorders. If subjects needed to be excluded from a group because of a lack of steady state in
the data (in- and efflux balance), individual subjects are mentioned.
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Page 9 of 16dyslipidemic subjects. This test also examined the differ-
ence in VLDL performance in relation to differences in
standard diagnostics: triglycerides, HDL cholesterol, and
LDL cholesterol. The parameters we introduce are com-
pletely novel; there is no similar diagnostic method that
we can compare them to. The differences with standard
diagnostics were expressed as the ability to correctly
predict the known normolipidemic or dyslipidemic state
from the diagnostic parameters. The test consisted of
two phases: first the predictive power of each diagnostic
separately, then the predictive power of multivariate
models. For the multivariate models we performed logis-
tic regression, we subsequently added LDL cholesterol,
HDL cholesterol, triglycerides and VLDL performance
as predictor variables. The diagnostic accuracy was
quantified using ROC curves [28]. We used both the
Area Under the Curve (AUC) and Partial Area Under
the Curve statistics (pAUC - for false positive rates <
0.2) [28] to quantify the predictive power of each sepa-
rate diagnostic and of each multivariate regression
model.
The new VLDL performance marker clearly differed
between normolipidemic and dyslipidemic subjects. Fig-
u r e3 as h o w sR O Cc u r v e st h a td e s c r i b eh o ww e l lL D L
cholesterol, HDL cholesterol, triglycerides, and VLDL
performance distinguished normolipidemic from dyslipi-
demic subjects. Figure 3b shows ROC curves of multi-
variate regression models that successively incorporate
these diagnostics for making the same distinction
together. Table 4 shows the partial area-under-the-curve
(pAUC) and area-under-the-curve AUC values, indicat-
ing diagnostic power for dyslipidemia, for each of the
regression models. The table shows that VLDL perfor-
mance distinguished normolipidemics better from dysli-
pidemics than the routine clinical chemistry parameters.
Also, VLDL performance improved the distinction when
used in combination with LDL cholesterol, HDL choles-
terol and triglycerides. When accepting no false posi-
tives, the model including VLDL performance had a
91% sensitivity for correctly identifying dyslipidemic
subjects, versus a 67% sensitivity when using only trigly-
cerides, HDLc and LDLc. Therefore, VLDL performance
had additional value for distinguishing dyslipidemic
from normolipidemic subjects compared to standard
diagnostics.
Dyslipidemic subgroups
Next, we examined the average value of our VLDL-
related diagnostic parameters for each of the studied
subgroups. This comparison included subject groups for
which no standard clinical chemistry parameters were
available (normolipidemic subjects from [17-22]) and
subject groups with specific genetic disorders. These
genetic disorders include LPL -/- [16], apoE 2/2 [17],
apoE 4/4 [17], homozygous familial hypercholesterole-
mia [19], homozygous familial defective apoB [29], and
S447X [30] - a single nucleotide polymorphism in the
LPL gene.
Figure 4 shows the average VLDL metabolism-ratios
for all included subject groups. The figure clearly indi-
cates that the normolipidemic groups (green and light-
green lines) had a higher VLDL performance (projection
onto the identity line) than dyslipidemic groups. Inter-
estingly, this mainly seems to be due to an increased
LPL lipolysis - production ratio in VLDL, although the
liver uptake - production ratio in VLDL is generally also
higher. In the dyslipidemic patients the VLDL ratios
were lower to a different extent. Hypothyroid patients
Figure 3 Receiver operating characteristic (ROC) curves for
dyslipidemia. These curves indicate how well a) single diagnostics
and b) multivariate regression models distinguish dyslipidemic
subjects from normolipidemic subjects. The models in b)
subsequently include LDLc, HDLc, TG, and VLDL performance in
cumulative fashion. The ROC curve indicates with what sensitivity
various diagnostics can identify dyslipidemic subjects, when varying
the acceptable false-positive rate. An ROC curve further away from
the 1-1 identity line indicates a better diagnostic. For example,
when not accepting false positives, the regression model including
LDLc, HDLc and TG has a sensitivity of 66% (0.66), while additionally
including the VLDL performance diagnostic results in a sensitivity of
91% (0.91).
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Page 10 of 16on T4 treatment (marked with ‘1’) seemed to have an
improved VLDL performance with respect to the
untreated patients (marked with ‘4’). Patients with small
LDL particles showed a relatively light dyslipidemia,
whereas mixed hyperlipidemia was associated with dif-
ferent degrees of dyslipidemia (’3’ and ‘8’). Kidney
patients, hypothyroid patients, and HIV-treated patients
fell in between the mixed hyperlipidemias. The patients
with genetic deficiencies showed up at the expected
locations. LPL deficient patients had the lowest VLDL
performance, and also the S447X polymorphism in this
gene negatively affected VLDL performance. ApoE 4/4
subjects, that are known to display a good VLDL clear-
ance, showed up together with the normolipidemics,
whereas apoE 2/2 subjects, known to have impaired
VLDL clearance, showed up as slightly dyslipidemic.
Response to treatment
Ad i a g n o s t i c ’s clinical usefulness increases if there are
treatment options when the diagnostic indicates illness.
Therefore, we investigated how our VLDL-related diag-
nostic parameters respond to treatment. For this pur-
pose we used data on atorvastatin and fenofibrate
treatment in mixed dyslipidemic subjects from Bilz et
al. [24], and atorvastatin and simvastatin treatment in
mixed dyslipidemic subjects from Forster et al. [25]. All
these studies contain lipoprotein kinetics data at base-
line and after each treatment, which we used as input
for Particle Profiler.
Figure 5 shows how the VLDL metabolism diagnostics
responded to treatment in mixed dyslipidemic patients.
Fenofibrate and simvastatin clearly raised VLDL perfor-
mance values. The effect of atorvastatin was borderline
significant in the study by Forster et al.[ 2 5 ] ,w h i l et h e
s t u d yb yB i l zet al. [24] had too few subjects to distin-
guish this effect. Therefore, we conclude that fenofibrate
and simvastatin have a stronger effect on VLDL perfor-
mance than atorvastatin.
Discussion
This study concerns the further development, calibra-
tion, and technical and clinical validation of the compu-
tational model Particle Profiler. Since no direct
measurements can be done for this validation, we inves-
tigated whether the model could be corroborated and
whether model-derived metabolic ratios for VLDL were
able to indicate relevant differences between normolipi-
demic and dyslipidemic subjects.
Model development and calibration
Model development involved introducing altered mathe-
matical functions to represent hepatic lipolysis and
uptake. The new model implementation had one less
free model parameter than the original implementation.
The newly fixed parameter contains the particle size at
which hepatic lipase (HL) activity is maximal. In
Table 4 Power of distinction between normolipidemic
and dyslipidemic subjects
Rank Diagnostic pAUC AUC
1 LDLc – HDLc – TG – VLDL performance 0.184 0.955
2 VLDL performance 0.167 0.937
3 LDLc – HDLc – TG 0.159 0.929
4 LDLc – HDLc 0.141 0.881
5 kVLDL
l
Jp,VLDL
0.133 0.893
6 TG (mmol/l) 0.130 0.900
7 HDLc (mmol/l) 0.112 0.790
8 LDLc (mmol/l) 0.099 0.794
9 kVLDL
u,liver
Jp,VLDL
0.071 0.783
Partial area under the curve (pAUC) and area under the curve (AUC)
calculated from ROC curves of various diagnostics and combinations of
diagnostics for distinguishing dyslipidemic subjects from normolipidemic
subjects. Both pAUC and AUC are a measure of how well each diagnostic
predicts the dyslipidemic status, with the difference that the pAUC only takes
into account those predictions for which the false positive rate is smaller than
0.2, while the AUC takes into account all possible false positive rates. The
higher the pAUC and AUC are, the better the diagnostic is.
Figure 4 The average VLDL performance of various subject
groups. Green lines with round ends are normolipidemic subject
groups. Groups indicated with darker green were used for the ROC
curve in figure 3, those indicated with light green were not. Red
lines with crosses represent dyslipidemic subject groups used for
the ROC curve. Groups are labeled as follows: 1) hypothyroid
patients during T4 treatment [26]; 2) subjects with small LDL peak
size [18]; 3 and 8) mixed hyperlipidemia [24,25]; 4) hypothyroid
patients before treatment [26]; 5) kidney disease: membranous
glomerulonephritis [21]; 6) patients on HIV treatment [23]; 7) kidney
disease: focal segmental glomerulosclerosis [21]. Blue lines with
triangles indicate subject groups with specific genetic variant. FDB:
Familial Defective ApoB (mostly heterozygote) [29]; FH: Familial
Hypercholesterolemia (homozygote) [19]; S447X: specific single
nucleotide polymorphism in the LPL gene [30].
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used published data from LPL deficient, apoE 3/3 and
apoE 2/2 subjects. The values that were determined for
the model constants indicate that HL mainly affects
smaller VLDL 2 and IDL particles, whereas LPL mainly
affects the larger VLDL 2 and VLDL 1 particles. This
result corresponds to the known activity of these
enzymes [10,16,31].
The calibrated model produced an analysis of lipopro-
tein kinetics data from Packard et al. [18], in which the
overall error was comparable to that found in the first
model implementation [13], while the new implementa-
tion had a smaller standard deviation of the error. It is
encouraging that with fewer free parameters the newly
optimized model had an approximately equal fit error.
The smaller standard deviation of the fit error indicates
that the three subjects for which the uptake flux was
not fitted well in the initial implementation were fitted
better in the current implementation.
In our first paper, we compared the modeled LDL
peak size between groups with measured differences in
LDL peak size [13]. As could be expected, modeling the
HL lipolysis with one less free parameter affected the
modeled difference of LDL peak size between groups,
because HL is mainly responsible for remodeling of
LDL. However, we still detect an LDL peak size differ-
ence between groups, although with less significance
than before. Closer inspection showed that the new
model indeed predicted less difference in HL lipolysis
between groups than before, again reflecting the less
refined representation of HL in the new model
implementation. Conversely, we detected clearer differ-
ences in LPL lipolysis. This last change is likely to be a
consequence of the model calibration performed with
data from genetically deficient subjects. This calibration
allowed a clearer distinction of which lipolysis process is
operating at what particle size. Therefore, the new
model implementation has become somewhat less suita-
ble to identify changes in the metabolism of LDL parti-
cles, but has gained power for analyzing the metabolism
of IDL and VLDL particles. Overall, we have carried out
a necessary simplification of the model, while keeping
the model performance stable.
Model corroboration
The only available option for the technical model valida-
tion was corroborating the model, since the model out-
comes cannot be measured directly. For this
corroboration, we applied the model to lipoprotein
kinetics data measured in a range of normolipidemic
and dyslipidemic subjects. The model corroboration
showed that Particle Profiler was able to fit most lipo-
protein kinetics data with an error of 8.8% ± 5.0%, disre-
garding a study [21] where VLDL2 levels were
abnormally high compared to other literature. In con-
clusion, Particle Profiler is able to accurately analyze
lipoprotein kinetics data from subjects with a wide
range of dyslipidemias. This corroborates the validity of
using the model to analyze lipoprotein flux data.
VLDL metabolic ratios
We studied VLDL metabolic ratios derived from Particle
Profiler. The VLDL performance diagnostic was able to
distinguish normolipidemic from dyslipidemic subjects.
It did so better than a multivariate regression model
including LDLc, HDLc and triglycerides, with a 5%
improved pAUC when used alone, and a 16% improved
pAUC when added to the multivariate model. These
results show that VLDL performance distinguished
between normolipidemic and dyslipidemic subjects more
clearly than standard clinical chemistry parameters.
In normolipidemics, the ratio between LPL lipolysis
and production in VLDL was generally higher than the
ratio between liver uptake and production in VLDL.
Since the normal physiological function of lipoproteins
is to transport triglycerides from the liver to other tis-
sues, it seems perfectly reasonable that extrahepatic
lipolysis of VLDL is more important than direct liver
uptake in normolipidemic subjects. Subjects with genetic
deficiencies showed up at the expected places in the
between-group comparison. LPL deficiency or impair-
ment greatly decreased VLDL performance, apoE 2/2
subjects had a slightly less impaired VLDL performance,
and apoE 4/4 subjects had a healthy VLDL performance,
all according to expectation. The FH patients showed a
Figure 5 VLDL performance response to treatment.A v e r a g e
VLDL performance response (on identity line) to Atorvastatin,
Simvastatin and Fenofibrate treatment in mixed hyperlipidemic
patients [24,25]. P-values for VLDL performance were calculated by
the Wilcoxon rank-sum test. Bilz Atorvastatin: n = 5, p = 0.0925; Bilz
Fenofibrate: n = 5, p = 0.0079; Forster Atorvastatin: n = 9, p =
0.0482; Forster Simvastatin: n = 11, p = 0.0006. All treatments
caused VLDL performance to move towards healthier values.
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ably because most FDB subjects were heterozygous and
the FH subjects homozygous. Treatment by atorvastatin,
simvastatin, and fenofibrate all positively influenced the
VLDL metabolism ratios, although atorvastatin did so
less clearly than the other two treatments. This result is
coherent with the findings in the original studies [24,25]
that all drugs increased VLDL turnover rates; also, in
both these studies atorvastatin affected the VLDL1 turn-
over less strongly than either fenofibrate or simvastatin.
Taken together, the results mentioned above show that
the VLDL metabolism ratios clearly reflect dyslipidemic
status, and that drug therapy improves dyslipidemia as
quantified by these ratios. These results constitute a first
indication of clinical usefulness of lipoprotein metabo-
lism ratios based on Particle Profiler.
Future development
We plan to conduct a further clinical validation of Parti-
cle Profiler-based metabolic ratios as predictors of cardi-
ovascular disease in a separate study. To this end we
will analyze relevant data from cohorts such as the Fra-
mingham Heart Study. Developing a similar approach to
Particle Profiler for HDL metabolism is also a future
possiblity. Since VLDL metabolism is known to be
affected in the ‘atherogenic lipoprotein phenotype’ [27],
there is reason to believe that parameters derived from
the current Particle Profiler implementation can contri-
bute to predicting cardiovascular disease risk. Parties
interested in working with Particle Profiler are requested
to contact TNO.
Conclusions
In this study we further developed, calibrated, and cor-
roborated the Particle Profiler computational model
using pooled lipoprotein metabolic flux data. From
pooled lipoprotein metabolic flux data on dyslipidemic
patients, we derived VLDL metabolic ratios that better
distinguished normolipidemic from dyslipidemic subjects
than standard diagnostics (HDLc, TG, LDLc). Since dys-
lipidemias are closely linked to cardiovascular disease
and diabetes type II development, lipoprotein metabolic
ratios are candidate risk markers for these diseases.
These ratios can in principle be obtained by applying
Particle Profiler to a single lipoprotein profile measure-
ment, which makes clinical application feasible.
Methods
Model Parametrisation: Overview
The model equations have been parameterized as
follows:
Production: no fitted parameters (eq. 1&2 in [13])
The Jin ’s are based directly on the dataset being fitted,
other values can be found in appendix 1.
Extrahepatic lipolysis: 1 fitted parameter (eq. 4 in
[13])
kl, max maximum rate at which extrahepatic lipolysis
takes place
2 fixed model constants:
dl, min minimum size at which extrahepatic lipolysis
occurs
sl shape parameter for extrahepatic lipolysis
Liver attachment, lipolysis and uptake: 5 fitted para-
meters (eqs. 1-3)
ka, apoEmax maximum rate at which liver binding
mediated by apoE takes place
ka, apoB rate at which liver binding mediated by apoB
takes place
A shape constant for liver binding mediated by apoE
B shape parameter for liver binding mediated by apoE
su, liver shape parameter describing how the fraction of
liver attachment which is taken up (instead of lipolized)
varies with particle size.
2 fixed model constants
Su, liver shape constant describing how the fraction of
liver attachment which is taken up (instead of lipolized)
varies with particle size.
dl, apoEmin minimum particle diameter at which liver
binding mediated by apoE takes place
Triglyceride loss during lipolysis (eq 8 in [13])
1 fixed model constant
ftg fraction of triglycerides lost at each lipolysis step
Model reparameterisation for fitting of flux data
Using the parameters specified above, the fitting routine
had difficulty to find the global minimum mean square
error. In order to improve its performance we specified
a reparametrisation, specific for the data type used in
this paper. This allows the fitting routine to find a mini-
mum without difficulty.
kl, max maximum rate at which extrahepatic lipolysis
takes place
(unchanged from original model)
B shape parameter for liver binding mediated by apoE.
(unchanged from original model)
su, liver shape parameter describing how the fraction of
liver attachment which is taken up (instead of lipolized)
varies with particle size.
(unchanged from original model)
ka, apoB the liver attachment rate due to apoB-related
processes
(unchanged from original model)
kpeak the total rate of all processes at the particle size
at which hepatic lipolysis is at its peak (d=d hl, peak).
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dhl, peak Size at which hepatic lipolysis is at its peak
The new parameter is specified as follows:
kpeak = ka,liver(dhl,peak)+kl(dhl,peak) (5)
This specification of parameters may lead to problems
in the fitting routine in specific cases, when the bound-
ary values of processes are reached. Therefore, during
the parameter conversion process from fitted parameters
to parameters for model calculation, the following fitted
parameters were dynamically set to their boundary
value. This procedure means that a parameter is only
set to its boundary value if necessary, otherwise it is
fitted normally.
Condition: kpeak ≤ ka, apoB + kl, max
Set boundary: kpeak =k a, apoB + kl, max +0.00001
Condition: su, liver >2 5
Set boundary: su, liver =2 5
Condition:
B < 1+e
ln
⎛
⎜
⎝
d − da,livermin
s
1/2
u,liver · σu,liver
⎞
⎟
⎠·su,liver
· su,liver
Set boundary:
B =1+e
ln
⎛
⎜
⎝
d − da,livermin
s
1/2
u,liver · σu,liver
⎞
⎟
⎠·su,liver
· su,liver + 0.000001
Size classes
The size range of each size class are shown in Table 5.
Error function
The error function used in the nlinfit routine is shown
in Table 6. The lower weights of the larger particle
pools give them more importance in the fitting routine.
This is desirable since these pools are also important to
estimate the rate of the fluxes correctly.
To indicate the error value between the data and the
model fit a percentage error was defined. This score was
not used for model fitting, only for reporting an intui-
tive error score. It takes into account the number of
data points for pools, uptake and lipolysis and the
higher importance (double of the flux total) of the pool
sizes; they are most important for parameter estimation.
It is given by the following formula (eq. 6):
E =
⎧
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Where E stands for error value, Q indicates the pool
size, superscript d indicating the data and m the model
fit. J stands for a flux, superscripts d and m as before, l
indicates lipolysis, u indicates uptake. Subscript i indexes
the different data points of each lipolysis size class, i.e.
LDL, IDL, VLDL2 and VLDL1.
Conversions
The datasets of Packard et al. [18], Demant et al.
[16,17], and Bilz et al.[24] contain estimations for the
lipoprotein pools of the various classes in mg, and turn-
over speeds in pools per day. These are converted to
particle concentrations and particle fluxes respectively.
This needs the assumption that only ApoB-100 is pre-
sent on lipoprotein particles in the fasted state, which is
reasonable given that apoB-48 is produced by the intes-
tine mainly postprandially. The equation looks as fol-
lows (eq. 7):
n
 
mol
L
 
=
n
 
g
 
MApoB−100(g/mol) · Vblood(L)
Where n is the number of lipoproteins, MApoB-100 the
molar mass of ApoB-100 and Vblood the blood volume
of an individual person (taken to be 5 L).
Endnotes
1 article freely downloadable from http://www.jlr.org/
content/50/12/2398
Table 5 Size Classes
Subfraction Minimum size Maximum size
LDL 5 25.0
IDL 25.0 30.0
VLDL2 30.0 36.0
VLDL1 36.0 60
The size range of each size class has been estimated as shown in this table,
modified from [32].
Table 6 Error function
LDL IDL VLDL 2 VLDL 1
Particle pool scale factor (particles/fl) 3 2 2 1
Lipolysis efflux scale factor (min
-1) - 0.005 0.005 0.005
Uptake flux scale factor
(min
-1)
0.005 0.005 0.005 0.005
The nlinfit routine calculates a sum of square difference between data points
and model predictions. Before entering into this routine the data was scaled
a) to correct for different units of pools data and flux data and b) to indicate
the relative importance of each data point. This adjustment is specific for the
type of data used. Data and model predictions were divided by the scaling
factors shown in this table.
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Additional file 1: Motivation for the equations. A complete, step-by-
step motivation for the new equations introduced in this study.
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